ResMed Company Profile (NYSE:RMD)

ResMed trades on the New York Stock Exchange (NYSE) under the ticker symbol "RMD."

ResMed announced a quarterly dividend on Thursday, April 27th. Stockholders of record on Thursday, May 11th will be paid a dividend of $0.33 per share on Thursday, June 15th. This represents a $1.32 dividend on an annualized basis and a dividend yield of 1.69%. The ex-dividend date of this dividend is Tuesday, May 9th. View ResMed's Dividend History.

ResMed Inc. (NYSE:RMD) posted its quarterly earnings data on Thursday, April, 27th. The company reported $0.71 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $0.70 by $0.01. The business earned $514.20 million during the quarter, compared to analyst estimates of $525.84 million. ResMed had a net margin of 15.96% and a return on equity of 22.53%. ResMed's quarterly revenue was up 13.3% compared to the same quarter last year. During the same quarter last year, the business posted $0.68 EPS. View ResMed's Earnings History.

10 analysts have issued 1-year target prices for ResMed's stock. Their forecasts range from $50.00 to $72.00. On average, they anticipate ResMed's share price to reach $61.29 in the next twelve months. View Analyst Ratings for ResMed.

Here are some recent quotes from research analysts about ResMed stock:

• 1. According to Zacks Investment Research, "In the last one month, ResMed is trading significantly above the broader Medical Products industry. On the brighter side, ResMed’s product launches and strategies to gain traction in the SDB market are expected to boost its performance in the near term. Moreover, the company’s double-digit growth in mask sales raises optimism. Its recent published favorable study result on COPD is expected to open up new scope in this line. Yet, challenges like competitive bidding and reimbursement issues continue to plague the stock. Foreign exchange movements dented third-quarter earnings, thanks to the weaker Euro and stronger Australian dollar relative to the U.S. dollar. Rising operating expenses and a weak operating margin are other major woes for ResMed. The company’s last reported fiscal third quarter performance was also unimpressive." (7/6/2017)
• 2. Needham & Company LLC analysts commented, "RMD’s revenue and EPS beat consensus in F2Q17. RMD’s gross margin was lower than expected as price declines and mix (both product and geographic) were partially offset by manufacturing efficiencies and the Brightree acquisition. However, this was offset by lower than expected SG&A and R&D expense and RMD’s operating margin beat our estimate. Despite the headline results, this wasn’t a clean quarter in our view since flow generator growth of 17% CC was helped by a few temporary factors (the AirStart liquidation and some stocking orders in China), mask growth was disappointing at 2% CC, and gross margin declined significantly on an organic basis." (1/24/2017)

Some companies that are related to ResMed include Cerner Corporation (CERN), Agilent Technologies (A), Waters Corporation (WAT), Hologic (HOLX), Varian Medical Systems (VAR), PerkinElmer (PKI), ABIOMED (ABMD), Bruker Corporation (BRKR), Alere (ALR), Accelerate Diagnostics (AXDX), Natus Medical Incorporated (BABY), Quidel Corporation (QDEL), ABAXIS (ABAX), Mazor Robotics (MZOR), Luminex Corporation (LMNX), GenMark Diagnostics (GNMK), LeMaitre Vascular (LMAT) and Accuray Incorporated (ARAY).

ResMed's management team includes the folowing people:

• Rob Douglas, President, Chief Operating Officer
• Michael Farrell, Chief Executive Officer, Director
• Brett A. Sandercock, Chief Financial Officer
• Jim Hollingshead Ph.D., President - Americas
• Anne Reiser, President – Europe & Asia Pacific
• David Pendarvis, Chief Administrative Officer, Global General Counsel, Company Secretary
• Agnes Lee, Senior Director - Investor Relations
• Peter C. Farrell Ph.D., Non-Executive Chairman of the Board
• Ron Taylor, Lead Independent Director
• Carol J. Burt, Independent Director

ResMed's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include APG Asset Management N.V. (0.22%), Capital Investment Services of America Inc. (0.15%), Professional Advisory Services Inc. (0.13%), Rockefeller Financial Services Inc. (0.13%), National Pension Service (0.11%) and BTIM Corp. (0.08%). Company insiders that own ResMed stock include Anne Reiser, Brett Sandercock, Christopher G Roberts, David Pendarvis, Donald Darkin, Franz Kozich, Gary W Pace, James Hollingshead, John P Wareham, Jr Gregor K Emmert, Michael J Farrell, Peter C Farrell, Richard Sulpizio, Robert Andrew Douglas, Ronald R Taylor and Warren Russell Hawkins. View Institutional Ownership Trends for ResMed.

ResMed's stock was sold by a variety of institutional investors in the last quarter, including Bank of Montreal Can, APG Asset Management N.V., Professional Advisory Services Inc., Assenagon Asset Management S.A., Capital Investment Services of America Inc., US Bancorp DE, B & T Capital Management DBA Alpha Capital Management and DnB Asset Management AS. Company insiders that have sold ResMed stock in the last year include Brett Sandercock, Christopher G Roberts, David Pendarvis, Gary W Pace, James Hollingshead, John P Wareham, Michael J Farrell, Peter C Farrell, Richard Sulpizio and Ronald R Taylor. View Insider Buying and Selling for ResMed.

ResMed's stock was bought by a variety of institutional investors in the last quarter, including BB&T Corp, Mn Services Vermogensbeheer B.V., Gateway Investment Advisers LLC, National Pension Service, Aperio Group LLC, BTIM Corp., West Coast Financial LLC and Oregon Public Employees Retirement Fund. Company insiders that have bought ResMed stock in the last two years include Franz Kozich, Jr Gregor K Emmert, Ronald R Taylor and Warren Russell Hawkins. View Insider Buying and Selling for ResMed.

Shares of ResMed can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of ResMed stock can currently be purchased for approximately $78.03.